Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Test Subject Dies While Taking Experimental Drug
A man taking part in a French drug trial died in January while undergoing treatment with an experimental painkiller drug. He was one of 90 healthy men who had volunteered to be tested with the drug, which was being developed by Bial, a Portuguese pharmaceuticals company. The volunteers were given the medication in differing amounts, and at different times. In all, six test subjects had to be hospitalized, and it was feared that three of them might have suffered brain injuries from the medication. Other test subjects had been treated in clinical trials before this group, with no major adverse reactions.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
This article explores legal developments over the past year that may impact compliance officer personal liability.